Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Want to see HK:2252 full AI Analyst Report?
Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$31.00
▼(-9.20% Downside)
Action:ReiteratedDate:05/02/26
The score is held back primarily by weak financial quality—continued net losses, deeply negative ROE, and ongoing cash burn—despite strong 2025 revenue acceleration and improved leverage. Technicals are supportive with an upward trend and positive MACD, but valuation remains difficult to justify on earnings due to negative P/E.
Positive Factors
Strong revenue acceleration (2025)
A sustained jump to ~61% revenue growth in 2025 signals improving commercial traction and market adoption of the company’s surgical robotic platforms. Over 2–6 months this supports scale benefits: higher unit volumes can amortize fixed R&D and sales costs, enabling a credible pathway to sustained margin improvement if growth persists.
Negative Factors
Persistent negative operating and free cash flow
Repeated negative operating and free cash flow means the company remains reliant on external financing or asset sales to fund operations. Over months this constrains capital allocation, risks dilution or higher-cost debt, and limits the firm’s ability to self-fund commercialization and after-sales support critical to medical device adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue acceleration (2025)
A sustained jump to ~61% revenue growth in 2025 signals improving commercial traction and market adoption of the company’s surgical robotic platforms. Over 2–6 months this supports scale benefits: higher unit volumes can amortize fixed R&D and sales costs, enabling a credible pathway to sustained margin improvement if growth persists.
Read all positive factors
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.83B
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)2.20
Revenue Growth114.97%
EPS Growth63.21%
CountryHK
Employees450
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)54.27
Price to Sales (P/S)41.54
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.00Price Target Upside17.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$1.09B
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic...
How the Company Makes Money
null...
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
45
Neutral
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 536.81M | 257.25M | 104.59M | 21.60M | 2.15M |
| Gross Profit | 153.57M | 86.22M | 14.69M | 6.56M | 919.00K |
| EBITDA | -87.31M | -413.34M | -893.36M | -1.05B | -543.84M |
| Net Income | -243.20M | -642.41M | -1.01B | -1.14B | -582.92M |
Balance Sheet | |||||
| Total Assets | 1.34B | 1.28B | 1.43B | 1.93B | 2.79B |
| Cash, Cash Equivalents and Short-Term Investments | 640.42M | 612.23M | 507.71M | 747.96M | 1.94B |
| Total Debt | 426.37M | 691.33M | 560.42M | 219.95M | 204.68M |
| Total Liabilities | 935.07M | 1.02B | 926.15M | 522.25M | 401.73M |
| Stockholders Equity | 410.85M | 278.20M | 519.48M | 1.42B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | -38.83M | -340.21M | -634.30M | -1.09B | -674.47M |
| Operating Cash Flow | -36.30M | -298.12M | -567.84M | -898.48M | -540.49M |
| Investing Cash Flow | 2.55M | -47.60M | -58.38M | -267.82M | -396.57M |
| Financing Cash Flow | 66.32M | 449.96M | 385.68M | -27.95M | 1.39B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Positive
34.14
Price Trends
26.55
Positive
25.41
Positive
24.55
Positive
Market Momentum
1.91
Negative
73.10
Negative
96.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Positive. The current price of 34.14 is above the 20-day moving average (MA) of 27.13, above the 50-day MA of 26.55, and above the 200-day MA of 24.55, indicating a bullish trend. The MACD of 1.91 indicates Negative momentum. The RSI at 73.10 is Negative, neither overbought nor oversold. The STOCH value of 96.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2252.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$7.11B | 8.20 | 11.91% | 1.26% | 10.19% | 23.70% | |
68 Neutral | HK$8.77B | 16.88 | 4.02% | ― | 5.10% | -32.48% | |
65 Neutral | HK$5.99B | 15.53 | 10.38% | 1.50% | 3.83% | -27.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$30.83B | -41.72 | -52.30% | ― | 114.97% | 63.21% | |
48 Neutral | HK$16.57B | 6.01 | 6.07% | ― | -3.62% | ― | |
42 Neutral | HK$3.07B | -1.03 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
29.02
10.16
53.87%
HK:0853
MicroPort Scientific
8.66
1.62
23.01%
HK:1302
LifeTech Scientific Corporation
2.00
0.43
27.47%
HK:1789
AK Medical Holdings Ltd.
6.33
0.88
16.15%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.37
-1.88
-44.24%
HK:2172
MicroPort NeuroTech Limited
10.50
0.25
2.44%
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
MicroPort MedBot Completes Near-Full H Share Circulation to Boost Liquidity
Apr 23, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd., a Hong Kong-listed Chinese medical technology company specializing in robotic-assisted surgical systems, continues to refine its capital structure to support its growth in domestic and global healthcare...
MicroPort MedBot Doubles Revenue as Toumai Surgical Robot Drives Overseas Surge
Mar 26, 2026
Shanghai MicroPort MedBot reported a sharp ramp-up in commercial performance for 2025, with revenue surging 114.2% year-on-year to RMB551.1 million, driven primarily by breakthrough progress in the rollout of its Toumai laparoscopic surgical robot...
Shanghai MicroPort MedBot Sets March 2026 Board Meeting to Approve 2025 Results
Mar 16, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled a board meeting for 26 March 2026 to review and approve the audited financial results for the year ended 31 December 2025 and to authorize their release. The board will also consider whethe...
MicroPort MedBot Wins HKEX Nod for Full Circulation of Nearly 6 Million H Shares
Feb 13, 2026
Shanghai MicroPort MedBot (Group) Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing and trading of 5,989,798 converted H shares. These shares were previously unlisted and will now enter full H share circulation, exp...
MicroPort MedBot’s Toumai Surgical Robot Surpasses 200 Global Orders
Feb 12, 2026
Shanghai MicroPort MedBot announced that its flagship Toumai laparoscopic surgical robot has secured more than 200 commercial orders worldwide, with about 130 systems already installed across nearly 50 countries and regions. The order momentum und...
MicroPort MedBot Gains CSRC Nod for 5.99 Million H-Share Conversion
Feb 4, 2026
Shanghai MicroPort MedBot received CSRC approval to convert 5,989,798 previously unlisted shares held by two shareholders into H shares, representing about 0.58% of its total share capital, paving the way for trading on the Hong Kong Main Board pe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.